(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P02428-C1

Total Pages in this Submission

■7

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent appli	cation for an
invention entitled: Dexamethasone Gel	<u>2</u>
	U.S. P7
and invented by:	100
Gunther Bellmann, Gudrun Claus-Herz and Christoph Kessler	83
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:	
☑ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:	09/486,460
Which is a:	
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:	
Which is a:	
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:	
Enclosed are:	
Application Elements	
1. 🗵 Filing fee as calculated and transmitted as described below	
2. Specification having pages and including the following:	
a. 🗵 Descriptive Title of the Invention	
b. Cross References to Related Applications (if applicable)	
c. Statement Regarding Federally-sponsored Research/Development (if applicable)	
d. Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix	
e. 🗵 Background of the Invention	
f. 🗵 Brief Summary of the Invention	
g. Brief Description of the Drawings (if filed)	
h. 🗵 Detailed Description	
i. 🗵 Claim(s) as Classified Below	
.,	
j. 🗵 Abstract of the Disclosure	

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P02428-C1

Total Pages in this Submission

		Application Elements (Continued)
3.		Drawing(s) (when necessary as prescribed by 35 USC 113)
	a.	□ Formal Number of Sheets
	b.	☐ Informal Number of Sheets
4.	\boxtimes	Oath or Declaration
	a.	☐ Newly executed (original or copy) ☐ Unexecuted
	b.	☑ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
	C.	☑ With Power of Attorney ☐ Without Power of Attorney
	d.	☐ <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.	X	Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7.	X	Application Data Sheet (See 37 CFR 1.76)
8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
	a.	☐ Computer Readable Form (CRF)
	b.	☐ Specification Sequence Listing on:
		i. CD-ROM or CD-R (2 copies); or
		ii. ☐ Paper
	C.	☐ Statement(s) Verifying Identical Paper and Computer Readable Copy
		Accompanying Application Parts
9.		Assignment Papers (cover sheet & document(s))
10.		37 CFR 3.73(B) Statement (when there is an assignee)
11.		English Translation Document (if applicable)
12.	X	Information Disclosure Statement/PTO-1449 Copies of IDS Citations
13.	X	Preliminary Amendment
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	\boxtimes	Certificate of Mailing
		☐ First Class ☒ Express Mail (Specify Label No.): EI748247299US

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P02428-C1

Total Pages in this Submission

		Accompanying Application Parts (Continued)
17.		Additional Enclosures (please identify below):
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
18.	0	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

Page 3 of 4

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **P02428-C1**

Total Pages in this Submission

Fee Calculation and Transmittal

		CLAIMS A	AS FILED			
For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	10	- 20 =	0	x	\$18.00	\$0.00
Indep. Claims	1	- 3 =	0	х	\$84.00	\$0.00
Multiple Dependent	Claims (check	if applicable)				\$0.00
					BASIC FEE	\$740.00
OTHER FEE (speci	fy purpose)					\$0.00
			i	-	TOTAL FILING FEE	\$740.00
as described bel ☑ Charge ☑ Credit a ☑ Charge ☐ Charge	ner is hereby aut ow. A duplicate the amount of ny overpayment any additional fil	horized to charge copy of this shee \$740.00 a ing fees required in 37 C.F.R. 1.18	et is enclosed is filing fee. under 37 C.f	eposit <i>i</i>	Account No. 02-1425	
Dated: September), ₂₀₀₃		Ва		Signature homas Lomb Incorporated ch & Lomb Place	

cc:

Rochester, New York 14604-2701 Telephone: (585) 338-8969

TRANSMITTAL LETTER Docket No. P02428-C1 (General - Patent Pending) In Re Application Of: Bellmann, et al. Serial No. Filing Date Examiner **Group Art Unit** September 18, 2003 N/A Not Yet Assigned N/A Title: DEXAMETHASONE GEL TO THE ASSISTANT COMMISSIONER FOR PATENTS: Transmitted herewith is: Utility Patent Application Transmittal (Continuation of 09/486,460) **Preliminary Amendment Application Data Sheet** Certificate of Mailing Return Receipt Card in the above identified application. No additional fee is required. A check in the amount of is attached. 02-1425 ☑ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. Charge the amount of \$740.00 \boxtimes Credit any overpayment. Charge any additional fee required. Dated: September / O, 2003 Signature John E.\Thomas Registration No. 34,070 Bausch & Lomb Incorporated certify that this document and fee is being deposited on One Bausch & Lomb Place with the U.S. Postal Service as first Rochester, New York 14604-2701 class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. Telephone: 585/338-8969

20231.

Signature of Person Mailing Correspondence

Laura A. Galletto

Typed or Printed Name of Person Mailing Correspondence

CERTIFICATE OF M Applicant(s): Bellmann, et Serial No. Not Yet Assigned	Filing Date September 18, 2003	MAIL" (37 CFR 1.10) Examiner	Docket No. P02428-C1 Group Art Unit
		Examiner	Group Art Unit
		N/A	N/A
Invention: Dexamethason	e Gel		
I hereby certify that the t	following correspondence:		
Utility Patent Applictaio Preliminary Amendment Application Data Sheet	on Transmittal (Continuation of t	09/486,460)	
	(Identify type o	of correspondence)	
is being deposited with t	the United States Postal Servi	ce "Express Mail Post Office to A	Addressee" service under
37 CFR 1.10 in an enve September ()	_ '	stant Commissioner for Patents,	Washington, D.C. 20231
		Laura A. Galle	
		(Typed or Printed Name of Person Main	ling Correspondence)
		(Signature of Person Mailing Co	rrespondence)
		EI748247299U	

Note: Each paper must have its own certificate of mailing.